A role for atm in E-cadherin-mediated contact inhibition in epithelial cells

Breast Cancer Research and Treatment

Volumn 99, Issue 2, 2006, Pages 143-153

  Vutskits, Geneviève Vaudan ^a   Salmon, Patrick ^a   Mayor, Laurence ^a   Vutskits, Laszlo ^b   Cudré Mauroux, Christophe ^a   Soriano, Jesus ^a   Montesano, Roberto ^a   Maillet, Philippe ^a   Sappino, André Pascal ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atm; Breast cancer; Cell cycle arrest; Contact inhibition; E cadherin; Tis 21

Indexed keywords

ANTIBODY; ATM PROTEIN; CYCLIN A; CYCLIN B1; CYCLIN B2; CYCLIN E; UVOMORULIN;

ANIMAL CELL; ARTICLE; ATAXIA TELANGIECTASIA; CARCINOGENESIS; CELL CULTURE; CELL CYCLE REGULATION; CELL GROWTH; CELL SURFACE; CONTACT INHIBITION; CONTROLLED STUDY; CYTOLOGY; DOWN REGULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ATAXIA TELANGIECTASIA; CADHERINS; CELL ADHESION; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; CONTACT INHIBITION; CYCLINS; DNA-BINDING PROTEINS; EPITHELIAL CELLS; FEMALE; HELA CELLS; HUMANS; MAMMARY GLANDS, ANIMAL; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 33747615927     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9195-y     Document Type: Article

References (50)

1. Rotman G, Shiloh Y: ATM: from gene to function. Hum Mol Genet 7(10): 1555-1563, 1998
2. Swift Cancer predisposition of Ataxia-Telangiectasia heterozygotes. Cancer Genet Cytogenet 46: 21-27, 1990
3. Gumy-Pause F, Wacker P, Sappino AP: ATM gene and lymphoid malignancies. Leukemia 18(2): 238-242, 2004
4. Easton DF: Cancer risks in A-T heterozygotes. Int J Radiat Biol 66(6 Suppl): S177-182, 1994
5. Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, Scott G, Jacobs C, Liebmann R, Zvelebil MJ, Mathew C, Solomon E: Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer 26(4): 286-294, 1999
6. Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van't Veer LJ: ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet 66(2): 494-500, 2000
7. Maillet P, Bonnefoi H, Vaudan Vutskits G, Pajk B, Cufer T, Foulkes W, Chappuis PO, Sappino AP: Constitutional alterations of the ATM gene in early-onset sporadic breast cancer. J Med Genet 39(10): 751-753, 2002
8. Chen G, Lee E: The product of the ATM gene is a 370-kDa nuclear phosphoprotein. J Biol Chem 271(52): 33693-33697, 1996
9. Watters D, Khanna KK, Beamish H, Birrell G, Spring K, Kedar P, Gatei M, Stenzel D, Hobson K, Kozlov S, Zhang N, Farrell A, Ramsay J, Gatti R, Lavin M: Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms. Oncogene 14(16): 1911-1921, 1997
10. Brown KD, Chakravarti A: Multiple ATM-Dependent Pathways: An Explanation for Pleiotropy. Am J Hum Genet 64(1): 46-50, 1999
11. Zakian VA: ATM-related genes: what do they tell us about functions of the human gene?. Cell 82(5): 685-687, 1995
12. Bosotti R, Isacchi A, Sonnhammer EL: FAT: a novel domain in PIK-related kinases. Trends Biochem Sci 25(5): 225-227, 2000
13. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281(5383): 1677-1679, 1998
14. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, Barlow C, Baltimore D, Wynshaw-Boris A, Kastan MB, Wang JY: Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387(6632): 516-519, 1997
15. Barlow C, Brown KD, Deng CX, Tagle DA, Wynshaw-Boris A: Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet 17(4): 453-456, 1997
16. Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC, Isaacs WB: Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res 55(21): 4813-4817, 1995
17. Lowy AM, Knight J, Groden J: Restoration of E-cadherin/beta-catenin expression in pancreatic cancer cells inhibits growth by induction of apoptosis. Surgery 132(2): 141-148, 2002
18. Daniel CW, Strickland P, Friedmann Y: Expression and functional role of E- and P-cadherins in mouse mammary ductal morphogenesis and growth. Dev Biol 169(2): 511-519, 1995
19. Palacios J, Benito N, Pizarro A, Suarez A, Espada J, Cano A, Gamallo C: Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. Am J Pathol 146(3): 605-612, 1995
20. Berx G, Van Roy F: The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res(3): 289-293, 2001
21. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS: E-Cadherin-dependent growth suppression is mediated by the cyclin- dependent kinase inhibitor p27(KIP1). J Cell Biol 142(2): 557-571, 1998
22. Soriano JV, Pepper MS, Nakamura T, Orci L, Montesano R: Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells. J Cell Sci 108: 413-430, 1995
23. Montesano R, Soriano JV, Fialka I, Orci L: Isolation of EpH4 mammary epithelial cell subpopulations which differ in their morphogenetic properties. In vitro Cell Devel Biol-Animal 34: 468-477, 1998
24. Salmon P, Kindler V, Ducrey O, Chapuis B, Zubler RH, Trono D: High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96(10): 3392-3398, 2000
25. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracyclin-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551, 1992
26. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H: Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769, 1995
27. Pecker I, Avraham KB, Gilbert DJ, Savitsky K, Rotman G, Harnik R, Fukao T, Schrock E, Hirotsune S, Tagle DA, Collins FS, Wynshaw-Boris A, Ried T, Copeland NG, Jenkins NA, Shiloh Y, Ziv Y: Identification and chromosomal localization of Atm, the mouse homolog of the ataxia-telangiectasia gene. Genomics 35(1): 39-45, 1996
28. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259): 263-267, 1996
29. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871-875, 1997
30. PE Applied Biosystems User Bulletin #2, 1997
31. Soriano JV, Pepper MS, Orci L, Montesano R: Roles of hepatocyte growth factor/scatter factor and transforming growth factor-beta1 in mammary gland ductal morphogenesis. J Mammary Gland Biol Neoplasia 3(2): 133-150, 1998
32. Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB: Fragments of ATM which have dominant-negative or complementing activity. Mol Cell Biol 17(4): 2020-2029, 1997
33. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N: Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 273(45): 29864-29872, 1998
34. Levenberg S, Yarden A, Kam Z, Geiger B: p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. Oncogene 18(4): 869-876, 1999
35. Nakatsuji Y, Miller RH: Density dependent modulation of cell cycle protein expression in astrocytes. J Neurosci Res 66(3): 487-496, 2001
36. Rotman G, Shiloh Y: The ATM gene and protein: possible roles in genome surveillance, checkpoint controls and cellular defence against oxidative stress. Cancer Surv 29: 285-304, 1997
37. Rouault JP, Falette N, Guehenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R, Samarut J, Magaud JP, Ozturk M, Samarut C, Puisieux A: Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14(4): 482-488, 1997
38. Taylor WR, Agarwal ML, Agarwal A, Stacey DW, Stark GR: p53 inhibits entry into mitosis when DNA synthesis is blocked. Oncogene 18(2): 283-295, 1999
39. Muller KM, Luedecker CJ, Udey MC, Farr AG: Involvement of E-cadherin in thymus organogenesis and thymocyte maturation. Immunity 6(3): 257-264, 1997
40. Karecla PI, Bowden SJ, Green SJ, Kilshaw PJ: Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7). Eur J Immunol 25(3): 852-856, 1995
41. Shiloh Y: ATM (ataxia telangiectasia mutated): expanding roles in the DNA damage response and cellular homeostasis. Biochem Soc Trans 29(Pt 6): 661-666, 2001
42. Abbate M, Remuzzi G: Acceleration of recovery in acute renal failure: from cellular mechanisms of tubular repair to innovative targeted therapies. Ren Fail 18(3): 377-388, 1996
43. Filipak M, Estervig DN, Tzen CY, Minoo P, Hoerl BJ, Maercklein PB, Zschunke MA, Edens M, Scott RE: Integrated control of proliferation and differentiation of mesenchymal stem cells. Environ Health Perspect 80: 117-125, 1989
44. Vizirianakis IS, Chen YQ, Kantak SS, Tsiftsoglou AS, Kramer RH: Dominant-negative E-cadherin alters adhesion and reverses contact inhibition of growth in breast carcinoma cells. Int J Oncol 21(1): 135-144, 2002
45. Calaf G, Russo J, Tait L, Estrad S, Alvarado ME: Morphological phenotypes in neoplastic progression of human breast epithelial cells. J Submicrosc Cytol Pathol 32(1): 83-96, 2000
46. Delia D, Mizutani S, Panigone S, Tagliabue E, Fontanella E, Asada M, Yamada T, Taya Y, Prudente S, Saviozzi S, Frati L, Pierotti MA, Chessa L: ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and at heterozygotes. Br J Cancer 82(12): 1938-1945, 2000
47. Yang DQ, Kastan MB: Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2(12): 893-898, 2000
48. El-Bahrawy MA, Pignatelli M: E-cadherin and catenins: molecules with versatile roles in normal and neoplastic epithelial cell biology. Microsc Res Tech 43(3): 224-232, 1998
49. Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92(2): 130-134, 1996
50. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J: BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14(8): 927-939, 2000